Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication

EVP-6124, a selective alpha-7 partial agonist, has positive effects on cognition and clinical function in mild-to-moderate Alzheimer's disease patients: Results of a six-month, double-blind, placebo controlled, dose ranging study

(2014) Dana Hilt et al.   Alzheimers & Dementia

A PHASE 2 TRIAL OF THE EFFICACY AND SAFETY OF THE ALPHA7 AGONIST ABT-126 AS AN ADD-ON TREATMENT IN MILD-TO-MODERATE ALZHEIMER'S DEMENTIA

(2014) Laura M. Gault et al.   Alzheimers & Dementia

EFFICACY AND SAFETY OF THE ALPHA7 AGONIST ABT-126 AS A MONOTHERAPY TREATMENT IN MILD-TO-MODERATE ALZHEIMER'S DEMENTIA: RESULTS OF A PHASE 2B TRIAL

(2014) Ahmed Othman et al.   Alzheimers & Dementia

2014 Alzheimer's disease facts and figures

(2014)   Alzheimers & Dementia

Targeting Brain α7 Nicotinic Acetylcholine Receptors in Alzheimer’s Disease: Rationale and Current Status

(2014) Ana Sofía Vallés et al.   CNS DRUGS

NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimer’s Disease

(2014) Chieh-Hsin Lin et al.   CURRENT PHARMACEUTICAL DESIGN

Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition

(2014) SHELDON H. PRESKORN et al.   Journal of Psychiatric Practice

The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens

(2014) Mei Huang et al.   PSYCHOPHARMACOLOGY

Population pharmacokinetic modeling of EVP-6124 following oral administration

(2013) Steve Kuan et al.   Alzheimers & Dementia

EVP-6124, an alpha7 nicotinic acetycholine receptor partial agonist, did not delay cardiac repolarization in healthy subjects

(2013) Gordon Loewen et al.   Alzheimers & Dementia

Validation of a novel cognitive composite assessment for mild and prodromal Alzheimer's disease

(2013) John Harrison et al.   Alzheimers & Dementia

Efficacy and safety of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia

(2013) Laura Gault et al.   Alzheimers & Dementia

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

(2013) Parminder Raina et al.   ANNALS OF INTERNAL MEDICINE

Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians

(2013) Amir Qaseem   ANNALS OF INTERNAL MEDICINE

Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia

(2013) Jared W. Young et al.   BIOCHEMICAL PHARMACOLOGY

Restoring long-term potentiation impaired by amyloid-beta oligomers: Comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists

(2013) Katja S. Kroker et al.   BRAIN RESEARCH BULLETIN

Alzheimer disease in the United States (2010-2050) estimated using the 2010 census

(2013) L. E. Hebert et al.   NEUROLOGY

Nicotine Prevents Synaptic Impairment Induced by Amyloid-β Oligomers Through α7-Nicotinic Acetylcholine Receptor Activation

(2013) Nibaldo C. Inestrosa et al.   NEUROMOLECULAR MEDICINE

Monetary Costs of Dementia in the United States

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Intraindividual cognitive decline using a brief computerized cognitive screening test

(2012) David G. Darby et al.   Alzheimers & Dementia

Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials

(2012) Jesse M. Cedarbaum et al.   Alzheimers & Dementia

Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease

(2011) H. Rheinallt Parri et al.   BIOCHEMICAL PHARMACOLOGY

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors

(2011) Jos Prickaerts et al.   NEUROPHARMACOLOGY

Evp-6124: Safety, Tolerability And Cognitive Effects Of A Novel A7 Nicotinic Receptor Agonist In Alzheimer'S Disease Patients On Stable Donepezil Or Rivastigmine Therapy

(2010) Dana Hilt et al.   Alzheimers & Dementia

The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts

(2010) S. J. Cano et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Loss of  7 Nicotinic Receptors Enhances  -Amyloid Oligomer Accumulation, Exacerbating Early-Stage Cognitive Decline and Septohippocampal Pathology in a Mouse Model of Alzheimer's Disease

(2010) C. M. Hernandez et al.   JOURNAL OF NEUROSCIENCE

In Vitro Pharmacological Characterization of a Novel Selective  7 Neuronal Nicotinic Acetylcholine Receptor Agonist ABT-107

(2010) J. Malysz et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

RG3487, a Novel Nicotinic  7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents

(2010) T. L. Wallace et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

In Vivo Pharmacological Characterization of a Novel Selective  7 Neuronal Nicotinic Acetylcholine Receptor Agonist ABT-107: Preclinical Considerations in Alzheimer's Disease

(2010) R. S. Bitner et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Alzheimer's disease: clinical trials and drug development

(2010) Francesca Mangialasche et al.   LANCET NEUROLOGY

The use of PET in Alzheimer disease

(2010) Agneta Nordberg et al.   Nature Reviews Neurology

Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes

(2009) Simon Sydserff et al.   BIOCHEMICAL PHARMACOLOGY

Structural and functional diversity of native brain neuronal nicotinic receptors

(2009) Cecilia Gotti et al.   BIOCHEMICAL PHARMACOLOGY

TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia

(2009) T.A. Hauser et al.   BIOCHEMICAL PHARMACOLOGY

Glutamate–Dopamine Crosstalk in the Rat Prefrontal Cortex is Modulated by Alpha7 Nicotinic Receptors and Potentiated by PNU-120596

(2009) Phil D. Livingstone et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Review: Therapy for Alzheimer's disease: how effective are current treatments?

(2009) Krista L. Lanctôt et al.   Therapeutic Advances in Neurological Disorders

The nicotinic α 7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-β 1–42

(2008) Andreas Søderman et al.   BRAIN RESEARCH